Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PAG: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| GABRD | expressed_in | gene | 0.80 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 0 hypotheses
neurodegeneration | 2026-04-15 | 0 hypotheses
neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.636
neurodegeneration | 2026-04-07 | 0 hypotheses
protein folding | 2026-04-06 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Tau Spreading Network Mapping via Spatial Transcriptomics in PSP | clinical | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $520,000 |
| 4R-Tau Targeting Therapies for PSP and CBS | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Tau Propagation Causality Test — Does Tau Spread Drive Neurodegenerati | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Tau Co-Pathology in DLB Clinical Heterogeneity | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Levodopa Response Determinants in PSP — Biomarker-Guided Prediction St | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Desi | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Tau Pathology Initiation Zone Identification | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| PSP and CBS Biomarker Validation Study | clinical | ALS | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Map | validation | Parkinson's Disease | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Pre-Symptomatic Tau Detection in MAPT Mutation Carriers | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Iron Dyshomeostasis in MSA Pathogenesis Experiment | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanis | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Microbiome-Gut Barrier Signatures in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Int | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| SCFA-Mediated Neuroinflammation in Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Parkinson's Disease Subtype Classification — Precision Medicine Approa | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symp [PMID:36965781] | ["Ishola IO", "Awogbindin IO", "Olubodun | Neurotoxicology | 2023 | 1 |
| Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 po [PMID:31227597] | Snyder AG, Hubbard NW, Messmer MN, Kofma | Sci Immunol | 2019 | 1 |
| Effect of etching with potassium hydrogen difluoride and ammonium hydrogen diflu [PMID:31068549] | Akazawa N, Koizumi H, Nogawa H, Kodaira | Dent Mater J | 2019 | 1 |
| Synapse formation in the brain can be enhanced by co-administering three specifi [PMID:29031899] | Wurtman RJ | Eur J Pharmacol | 2017 | 1 |
| Engineered AAVs for efficient noninvasive gene delivery to the central and perip [PMID:28671695] | Chan KY, Jang MJ, Yoo BB, Greenbaum A, R | Nat Neurosci | 2017 | 1 |
| The Pediatric Imaging, Neurocognition, and Genetics (PING) Data Repository. [PMID:25937488] | Jernigan TL, Brown TT, Hagler DJ Jr, Aks | Neuroimage | 2016 | 1 |
| Toll-like receptor expression in the blood and brain of patients and a mouse mod [PMID:25522431] | Drouin-Ouellet J, St-Amour I, Saint-Pier | The international journal of n | 2014 | 1 |
| Regulation of Lipid Biology-Associated Gene Expression in Granulosa Cells in Hyp [PMID:41605187] | ["Berkel C"] | Lipids | 2026 | 0 |
| Meta-GWAS of Pig Semen Quality Traits Reveals Conserved Genes Regulating Mammali [PMID:41504393] | ["Lin Q", "Cai X", "Zhong Z", "Li T", "C | Advanced science (Weinheim, Ba | 2026 | 0 |
| Necl1 deficiency induces noradrenergic dysfunction and depressive-like states in [PMID:41308882] | ["Song J", "Wang L", "Suo J", "Ran K", " | Journal of affective disorders | 2026 | 0 |
| The contribution of phenolic endocrine-disrupting chemicals to breast cancer ris [PMID:41673191] | ["Dou Y", "Li X", "Li M", "Shang J", "Xu | Scientific reports | 2026 | 0 |
| Transcriptomics reveals new therapeutic targets for ovarian cancer. [PMID:41577183] | ["Feng Y", "Liu G"] | SLAS technology | 2026 | 0 |
| Noradrenergic inhibition of definitive POMC neurons through direct and indirect [PMID:41877438] | Lavoie O, Turmel A, Khouma A, Minbashi M | Journal of neuroendocrinology | 2026 | 0 |
| Gray matter structural and molecular signatures in Alzheimer's disease and late- [PMID:41419068] | Yang S, Wang X, Yan Y, Zhang J, Wei Y et | J Affect Disord | 2026 | 0 |
| Duloxetine Improves Early Clinical Outcomes Including Range of Motion, Functiona [PMID:41934361] | Han SC, Han J, Min YK, Han JW, Jeong HJ | Am J Sports Med | 2026 | 0 |
| External fixation versus reverse shoulder arthroplasty for proximal humerus frac [PMID:41940987] | Vadalà A, Benelli C, Suraci F, Carta B, | Arch Orthop Trauma Surg | 2026 | 0 |
| Modeling and simulation of conducting airways during continuous high-frequency o [PMID:41941967] | Huang X, Francis I, Gu Y, Saha SC | Respir Physiol Neurobiol | 2026 | 0 |
| Potential antidepressant properties of aminophylline in male mice exposed to chr [PMID:41945313] | Samante FI, Galangue CG, Avelino DC, Bel | Pharmacol Rep | 2026 | 0 |
| Robot-assisted immediate implant placement with the socket shield technique in t [PMID:41963213] | Wu J, Lin B, Yang S, Xu S, Li S | J Prosthet Dent | 2026 | 0 |
| Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeut [PMID:41465422] | Ahremenko E, Andreev A, Apushkin D, Kork | International journal of molec | 2025 | 0 |
Multi-agent debates referencing this entity
active · Rounds: 4 · Score: 0.50 · 2026-04-16
active · Rounds: 4 · Score: 0.50 · 2026-04-16
active · Rounds: 4 · Score: 0.50 · 2026-04-15
active · Rounds: 4 · Score: 1.00 · 2026-04-12
active · Rounds: 4 · Score: 0.54 · 2026-04-04
active · Rounds: 4 · Score: 0.50 · 2026-04-03
active · Rounds: 4 · Score: 0.51 · 2026-04-02